Jiang S., Zhou S., Liu H., Peng C., Zhang X., Zhou H., Wang Z., Lu Q. Concentrations of vanadium in urine with hypertension prevalence and blood pressure levels. Ecotoxicology and Environmental Safety. 2021;213:112028. DOI: 10.1016/j.ecoenv.2021.112028..
DOI: 10.1016/j.ecoenv.2021.112028
Hashmi K., Satya, Gupta S., Siddique A., Khan T., Joshi S. Medicinal applications of vanadium complexes with Schiff bases. Journal of Trace Elements in Medicine and Biology. 2023;79:127245. DOI: 10.1016/j.jtemb.2023.127245..
DOI: 10.1016/j.jtemb.2023.127245
Romanowski G., Budka J., Inkielewicz-Stepniak I. Synthesis, spectroscopic characterization, catalytic and biological activity of oxidovanadium(V) complexes with chiral tetradentate schiff bases. Molecules. 2023;28:7408. DOI: 10.3390/molecules28217408..
DOI: 10.3390/molecules28217408
Amaral L., Moniz T., Silva A., Rangel M. Vanadium compounds with antidiabetic potential. International Journal of Molecular Sciences. 2023;24(21):15675. DOI: 10.3390/ijms242115675..
DOI: 10.3390/ijms242115675
Buglyó P., Kiss T., Kiss E., Sanna D., Garribba E., Micera G. Interaction between the low molecular mass components of blood serum and the VO(IV)-DHP system (DHP=1,2-dimethyl-3-hydroxy-4(1H)-pyridinone). Journal of the Chemical Society, Dalton Transactions. 2002:2275–2282. DOI: 10.1039/b200688j..
DOI: 10.1039/b200688j
Ugone V., Sanna D., Sciortino G., Crans D. C., Garribba E. ESI-MS study of the interaction of potential oxidovanadium(IV) drugs and amavadin with model proteins. Inorganic Chemistry. 2020;59(14):9739–9755. DOI: 10.1021/acs.inorgchem.0c00969..
DOI: 10.1021/acs.inorgchem.0c00969
Rehder D. Biological and medicinal aspects of vanadium. Inorganic Chemistry Communications. 2003;6(5):604–617.
Tracey A. S., Gresser M. J., Parkinson K. M. Vanadium (V) oxyanions. Interactions of vanadate with oxalate, lactate, and glycerate. Inorganic Chemistry. 1987;26:629–638.
Tinkov A. A., Popova E. V., Polyakova V. S., Kwan O. V., Skalny A. V., Nikonorov A. A. Adipose tissue chromium and vanadium disbalance in high-fat fed Wistar rats. The Journal of Trace Elements in Medicine and Biology. 2015;29:176–181. DOI: 10.1016/j.jtemb.2014.07.006..
DOI: 10.1016/j.jtemb.2014.07.006
Fontaine J., Tavernier G., Morin N., Carpéné C. Vanadium-dependent activation of glucose transport in adipocytes by catecholamines is not mediated via adrenoceptor stimulation or monoamine oxidase activity. World Journal of Diabetes. 2020;11(12):622–643. DOI: 10.4239/wjd.v11.i12.622..
DOI: 10.4239/wjd.v11.i12.622
Zhang S., Yan L, Kim S. M. Vanadium-protein complex inhibits human adipocyte differentiation through the activation of β-catenin and LKB1/AMPK signaling pathway. PLOS ONE. 2020;15(9):e0239547. DOI: 10.1371/journal.pone.0239547..
DOI: 10.1371/journal.pone.0239547
Kostrzewa T., Jończyk J., Drzeżdżon J., Jacewicz D., Górska-Ponikowska M., Kołaczkowski M., Kuban-Jankowska A. Synthesis, in vitro, and computational studies of PTP1B phosphatase inhibitors based on oxovanadium(IV) and dioxovanadium(V) complexes. International Journal of Molecular Sciences. 2022;23(13):7034. DOI: 10.3390/ijms23137034..
DOI: 10.3390/ijms23137034
Shaik A., Kondaparthy V., Begum A., Husain A., Manwal D. D. Enzyme PTP-1B inhibition studies by vanadium metal complexes: a kinetic approach. Biological Trace Element Research. 2023;201(10):5037–5052. DOI: 10.1007/s12011-023-03557-8..
DOI: 10.1007/s12011-023-03557-8
Cam M. C., Brownsey R. W., McNeill J. H. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? Canadian Journal of Physiology and Pharmacology. 2000;78(10):829–847.
Ajmani S., Karanam S., Kulkarni S. A. Rationalizing protein-ligand interactions for PTP1B inhibitors using computational methods. Chemical Biology & Drug Design. 2009;74(6):582–595.
Irving E, Stoker A. W. Vanadium Compounds as PTP Inhibitors. Molecules. 2017;19;22(12):2269. DOI: 10.3390/molecules22122269..
DOI: 10.3390/molecules22122269
Ramírez-Espinosa J. J., Rios M. Y., Paoli P., Flores-Morales V., Camici G., de la Rosa-Lugo V., Hidalgo-Figueroa S., Navarrete-Vázquez G., Estrada-Soto S. Synthesis of oleanolic acid derivatives: In vitro, in vivo and in silico studies for PTP-1B inhibition. The European Journal of Medicinal Chemistry. 2014;87:316–327.
Ghalichi F., Ostadrahimi A., Saghafi-Asl M. Vanadium and diabetic dyslipidemia: A systematic review of animal studies. The Journal of Trace Elements in Medicine and Biology. 2022;71:126955. DOI: 10.1016/j.jtemb.2022.126955..
DOI: 10.1016/j.jtemb.2022.126955
Kiss T., Jakusch T., Hollender D., Dörnyei Á., Enyedy É. A., Pessoa J. C., Sakurai H., Sanz-Medel A. Biospeciation of antidiabetic VO(IV) complexes. Coordination Chemistry Reviews. 2008;252:1153–1162.
Trevino S., Diaz A. Vanadium and insulin: partners in metabolic regulation. Journal of Inorganic Biochemistry. 2020;208:111094. DOI: 10.1016/j.jinorgbio.2020.111094..
DOI: 10.1016/j.jinorgbio.2020.111094
Sanna D., Garribba E. Pharmacologically active vanadium species: distribution in biological media and interaction with molecular targets. Current Medicinal Chemistry. 2021;28(35):7339–7384. DOI: 10.2174/0929867328666210531144021..
DOI: 10.2174/0929867328666210531144021
Mohammad A., Sharma V., McNeil J. H. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Mol. Cell. Biochem. 2002;233:139–143. DOI: 10.1023/a:1015558328757..
DOI: 10.1023/a:1015558328757
Treviño S., Díaz A., Sánchez-Lara E., Sanchez-Gaytan B. L., Perez-Aguilar J. M., González-Vergara E. Vanadium in biological action: chemical, pharmacological aspects, and metabolic implications in diabetes mellitus. Biological Trace Element Research. 2019;188(1):68–98. DOI: 10.1007/s12011-018-1540-6..
DOI: 10.1007/s12011-018-1540-6
Kothandan S., Sheela A. DNA Interaction and cytotoxic studies on mono/di-oxo and peroxo-vanadium (V) complexes – A Review. Mini-Reviews in Medicinal Chemistry. 2021;21(14):1909–1924. DOI: 10.2174/1389557521666210308143522..
DOI: 10.2174/1389557521666210308143522
Crans D. C., Henry L., Cardiff G., Posner B. I. Developing vanadium as an antidiabetic or anticancer drug: a clinical and historical perspective. The Metal ions in life sciences. 2019;19. DOI: 10.1515/9783110527872-014..
DOI: 10.1515/9783110527872-014
Scibior A., Pietrzyk Ł., Plewa Z., Skiba A. Vanadium: risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends. The Journal of Trace Elements in Medicine and Biology. 2020;61:126508. DOI: 10.1016/j.jtemb.2020.126508..
DOI: 10.1016/j.jtemb.2020.126508
Woo L. C., Yuen V. G., Thompson K. H., McNeill J. H., Orvig C. Vanadyl-biguanide complexes as potential synergistic insulin mimics. Journal of Inorganic Biochemistry. 1999;30;76(3–4):251–257. DOI: 10.1016/s0162-0134(99)00152-x..
DOI: 10.1016/s0162-0134(99)00152-x
Sakurai H., Hamada Y., Shimomura S. Cysteine methyl ester-oxovanadium (IV) complex, preparation and characterization. Inorganica Chimica Acta. 1980;46:119–120.
Cam M. C., Cros G. H., Serrano J. J., Lazaro R., McNeill J. H. In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes. Diabetes Research and Clinical Practice. 1993;20(2):111–121. DOI: 10.1016/0168-8227(93)90004-o..
DOI: 10.1016/0168-8227(93)90004-o
Sakurai H., Kojima Y., Yoshikawa Y. Kawabe К. Antidiabetic vanadium (IV) and zinc (II) complexes. Coordination Chemistry Reviews. 2002;226:187–189.
Sakurai H., Tsuchiya K., Nukatsuka M. Insulin-mimetic action of vanadyl complexes. Journal of Clinical Biochemistry and Nutrition. 1990;8:193–200.
Bergeron A., Kostenkova K., Selman M., Murakami H. A., Owens E., Haribabu N., Arulanandam R., Diallo J. S., Crans D. C. Enhancement of oncolytic virotherapy by vanadium(V) dipicolinates. Biometals. 2019;32(3):545–561. DOI: 10.1007/s10534-019-00200-9..
DOI: 10.1007/s10534-019-00200-9
Watanabe H., Nakai M., Komazawa K., Sakurai H. A new orally active insulin-mimetic vanadyl complex: bis(pyrrolidine-N-carbodithioato)oxovanadium (IV). Journal of Medicinal Chemistry. 1994;1;37(7):876–877. DOI: 10.1021/jm00033a002..
DOI: 10.1021/jm00033a002
Thompson K. H., Orvig C. Coordination chemistry of vanadium in metallopharmaceutical candidate compounds. Coordination Chemistry Reviews. 2001;219–221:1033–1035.
Sakurai H., Watanabe H., Tamura H. Insulin-mimetic vanadyl-dithiocarbamate complexes. Inorganica Chimica Acta. 1998;283(1):175–183.
Sathyanarayana D. N., Patel C. C. Studies on oxovanadium (IV) oxalate hydrates. Journal of Inorganic and Nuclear Chemistry. 1965;27(2):297–302.
Беляева Н. Ф., Городецкий В. К., Точилкин А. И., Голубев М. А., Семенова Н. В., Ковельман И. Р. Ванадийсодержащие соединения – новый класс терапевтических средств для лечения сахарного диабета. Вопросы медицинской химии. 2000;46(4):344–360.
Городецкий В. К., Точилкин А. И., Белаева Н. Ф., Ковельман И. Р., Коровкин Б. Ф. Синтез и гипогликемическая активность бис(L-малато)оксованадия (IV). Биомедицинская химия. 2011;57(1):133–137..
DOI: 10.18097/pbmc20115701133
Sathyanarayana D. N., Patel C. C. Simple malonate and maleate complexes of oxo-vanadium (IV). Bulletin of the Chemical Society of Japan. 1967;40(4):794–797.
Behzadi K., Thompson A. Preparation, characterization and reactions of vanadium (IV) β-diketonate complexes. Journal of the Less Common Metals. 1987;128:281–296.
Amin S. S., Cryer K., Zhang B., Dutta S. K., Eaton S. S., Anderson O. P., Miller S. M., Reul B. A., Brichard S. M., Crans D. C. Chemistry and insulin-mimetic properties of bis(acetylacetonate)oxovanadium (IV) and derivatives. Inorganic Chemistry. 2000;39(3):406–416. DOI: 10.1021/ic9905897..
DOI: 10.1021/ic9905897
Sheela A., Roopan S. M., Vijayaraghavan R. New diketone based vanadium complexes as insulin mimetics. European Journal of Medicinal Chemistry. 2008;43(10):2206–2210. DOI: 10.1016/j.ejmech.2008.01.002..
DOI: 10.1016/j.ejmech.2008.01.002
Saatchi K., Thompson K. H., Patrick B. O., Pink M., Yuen V. G., McNeill J. H., Orvig C. Coordination chemistry and insulin-enhancing behavior of vanadium complexes with maltol C6H6O3 structural isomers. Inorganic Chemistry. 2005;44(8):2689–2697. DOI: 10.1021/ic048186g..
DOI: 10.1021/ic048186g
McNeill J. H., Yuen V. G., Hoveyda H. R., Orvig C. Bis(maltolato)oxovanadium (IV) is a potent insulin mimic. Journal of Medicinal Chemistry. 1992;35(8):1489–1491. DOI: 10.1021/jm00086a020..
DOI: 10.1021/jm00086a020
Sakurai H., Katoh A., Kiss T., Jakusch T., Hattori M. Metallo-allixinate complexes with anti-diabetic and anti-metabolic syndrome activities. Metallomics. 2010;2(10):670–82. DOI: 10.1039/c0mt00025f..
DOI: 10.1039/c0mt00025f
Sakurai H., Tamura A., Fugono J. New antidiabetic vanadyl–pyridone complexes: effect of equivalent transformation of coordinating atom in the ligand. Coordination Chemistry Reviews. 2003;245(1–2):31–37.
Storr T., Mitchell D., Buglyó P., Thompson K. H., Yuen V. G., McNeill J. H., Orvig C. Vanadyl-thiazolidinedione combination agents for diabetes therapy. Bioconjugate Chemistry. 2003;14(1):212–221. DOI: 10.1021/bc025606m..
DOI: 10.1021/bc025606m
Shahzadi S., Ali S. Oxovanadium (IV) esters of ciprofloxacin: their characterization and potentiometric study. African Journal of Pure and Applied Chemistry. 2008;2(6):55–60.
Алеева Г. Н., Киясов А. П., Бурыкин И. М., Хафизьянова Р. Х. Сравнительная оценка клеточных механизмов реализации противодиабетического действия нового органического соединения оксованадия (IV) и ванадилсульфата. Экспериментальная и клиническая фармакология. 2004;67(3):42–44.
Naglah A. M., Al-Omar M. A., Almehizia A. A., Bhat M. A., Afifi W. M., Al-Wasidi A. S., Al-Humaidi J. Y., Refat M. S. A Novel Oxidovanadium (IV)-Orotate Complex as an Alternative Antidiabetic Agent: Synthesis, Characterization, and Biological Assessments. BioMed Research International. 2018;23;8108713. DOI: 10.1155/2018/8108713..
DOI: 10.1155/2018/8108713
Сидорова Ю. С., Скальная М. Г., Тиньков А. А., Мазо В. К. Влияние соединений ванадия на нарушения углеводного и жирового обмена. Проблемы Эндокринологии. 2019;65(3):184–190. DOI: 10.14341/probl10093..
DOI: 10.14341/probl10093
Shechter Y., Goldwaser I., Mironchik M., Fridkin M., Gefel D. Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coordination Chemistry Reviews. 2003;237:3–11.
Пулина Н. А., Кузнецов А. С., Краснова А. И., Новикова В. В. Синтез, антимикробная активность и влияние на поведенческие реакции N-замещенных гидразидов 4-арил-2-гидрокси-4-оксобут-2-еновых кислот и их комплексных производных. Химико-фармацевтический журнал. 2019;53(3):30–34. DOI: 10.30906/0023-1134-2019-53-3-30-34..
DOI: 10.30906/0023-1134-2019-53-3-30-34
Собин Ф. В., Пулина Н. А., Липатников К. В., Старкова А. В., Юшкова Т. А., Наугольных Е. А. Синтез, гемостатическая, противовоспалительная и антигельминтная активность производных 2-гидрокси-4-оксо-4-(тиен-2-ил)бут-2-еновой кислоты. Химико-фармацевтический журнал. 2020;54(10):21–25. DOI: 10.30906/0023-1134-2020-54-10-21-25..
DOI: 10.30906/0023-1134-2020-54-10-21-25
Собин Ф. В., Пулина Н. А., Липатников К. В., Старкова А. В., Юшкова Т. А., Наугольных Е. А. Синтез, гемостатическая, противовоспалительная и антигельминтная активность производных 2-гидрокси-4-оксо-4-(тиен-2-ил)бут-2-еновой кислоты. Химико-фармацевтический журнал. 2020;54(10):21–25. DOI: 10.30906/0023-1134-2020-54-10-21-25..
DOI: 10.1007/s11094-021-02310-6
Пулина Н. А., Юшкова Т. А., Краснова А. И. Биологическая активность бис[3-(4-хлорфенил)-1-(4-метилфенил)карбоксамидо-1,3-пропандионато]оксованадия. Химико-фармацевтический журнал. 2015;49(7):29–32.
Пулина Н. А., Собин Ф. В., Краснова А. И. Поиск отечественных фармацевтических субстанций в ряду металлокомплексов на основе (гет)ариламидов 4-арил-2-гидрокси-4-оксо-2-бутеновых кислот. Координационная химия. 2023;49(10):644–650. DOI: 10.31857/S0132344X23600182..
DOI: 10.31857/S0132344X23600182